Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).

Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). Circulation. 2016 Dec 13; 134(24):1918-1930.

View in: PubMed

subject areas

Acute Disease
Adult
Aged
Alanine Transaminase
Bilirubin
Biomarkers
Creatinine
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Female
Half-Life
Hemorrhage
Humans
Lipoproteins, HDL
Male
Middle Aged
Myocardial Infarction
Placebo Effect
Proportional Hazards Models
Treatment Outcome

authors with profiles

Robert Harrington